Clinical Trials Browser

INDUSTRY × Neurofibroma, Plexiform × AZD 6244 × Clear all

NCT04590235 2026-01-30

A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

Phase 1 Active not recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT04924608 2026-01-12

KOMET

Phase 3 Active not recruiting

145 enrolled 17 charts 1 FDA

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT05825365 2023-08-14

PROTECT

Phase 2 Withdrawn

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT03259633 2020-05-01

An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1

Approved for marketing

Neurofibroma, Plexiform